anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sprayable emulsions are provided. The emulsions can be used to treat various skin conditions. The emulsion comprises a hydrofluoro-based propellant, an emulsification system, an oil phase, an aqueous phase, and active agent particles. Furthermore, the emulsifying system comprises at least one non-ionic emulsifier. The emulsion has a viscosity of from about 500 centipoise to about 10,000 centipoise and a hydrophilic-lipophilic balance (HLB) value of from about 2 to about 12. The present inventors have found that by selectively controlling the nature of the emulsifying system and the viscosity of the emulsion, the active agent particles resist settling, thereby maintaining a substantially uniform distribution of active agent particles, and once applied can be uniformly sprayed onto a surface without flowing.
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of Part 1, Part 2 and the Japan and China monotherapy cohorts Part 1A will evaluate safety and target modulation of mevrometostat monotherapy in patients with SCLC, FL and CRPC. Mevrometostat will be administered as monotherapy in escalating doses to patients with FL (Part 1B) and mCRPC (Part 1C) to determine the monotherapy MTD. In Part 2A (dose escalation, RP2D finding for dose escalation), mevrometostat will be administered in combination with SOC to patients with mCRPC and SCLC. Japan and China monotherapy cohorts will evaluate the safety, antitumor activity and PK of single agent mevrometostat in Japanese and Chinese patients. In Part 2B (dose expansion), patients with mCRPC will be randomized (1:1 ratio) to receive either SOC or mevrometostat in combination with SOC. Part 2B will assess the efficacy of mevrometostat at the RP2D in combination with SOC in patients with mCRPC in comparison to SOC alone. Part 2C will explore the efficacy of mevrometostat given at a different dose/dosing regimen than 2B in combination with SOC in patients with mCRPC.
[PROBLEMS] To provide a tablet containing a dietary fiber at a high ratio, a dietary fiber tablet containing an essential oil and a method of producing these tablets. [MEANS FOR SOLVING PROBLEMS] A method of producing a tablet containing sodium alginate which comprises tabletting a sodium alginate powder; a method of producing a tablet containing sodium alginate characterized by comprising tabletting a sodium alginate powder and impregnating the obtained tablet with an essential oil; and sodium alginate-containing tablets produced by these production methods. Since sodium alginate can be directly tabletted by compressing a powder, a tablet consisting of sodium alginate alone can be prepared. Thus, a tablet having a large dietary fiber content per unit amount can be obtained. Compared with other tabletting methods, moreover, the above method is advantageous in employing a smaller number of steps and not requiring a high temperature. Furthermore, the tablet thus obtained is highly compatible with an essential oil and thus the essential oil is carried by the tablet in a stable state while showing little oil oozing.
AIM: Predicting neurodevelopmental outcomes in hypoxic-ischaemic encephalopathy (HIE) remains imprecise, despite advanced imaging and neurophysiological tests. We explored the predictive value of socio-economic status (SES).
METHODS: The cohort comprised 93 infants (59% male) with HIE, who had received therapeutic hypothermia. Patients underwent magnetic resonance imaging, and brain injuries were quantified using the Barkovich scoring system. Family SES was self-reported using a questionnaire. Adverse outcomes were defined as mild to severely delayed development with a score of ≤85 in any domain at 2 years of age, based on the Bayley Scales of Infant Development, Second Edition. Data are presented as odds ratios (OR) with 95% confidence intervals (95% CI).
RESULTS: Multiple regression modelling revealed that higher parental education was strongly associated with good cognitive development, when adjusted for gestational age, serum lactate and brain injuries (OR 2.20, 95% CI 1.16-4.36). The effect size of parental education (β = 0.786) was higher than one score for any brain injury using the Barkovich scoring system (β = -0.356). The literacy environment had a significant effect on cognitive development in the 21 infants who had brain injuries (OR 40, 95% CI 3.70-1352).
CONCLUSION: Parental education and the literacy environment influenced cognitive outcomes in patients with HIE.
Bis-aminomethyl-anthraquinone derivs. of formula (I) and their salts with acids are new. R1 and R2 are each H or 1-4C alkyl, or R1 and R2 together form a 4-6C alkylene residue so that N(R1)(R2) is a 5- to 7-membered heterocyclic ring which may contain N, O or S as a further heteroatom and which may be substd. by 1-4C alkyl; and R3 is H or OH). The new cpds. can be used for combatting protozoal diseases, in humans and animals, e.g. amoebiasis due to Entamoeba histolytica. In addn., the cpds. have a direct or (due to interferon-induction) indirect activity against influenza and encephalomyocarditis viruses. On account of their interferon-inducing activity, the cpds. can be used against virus and cancer diseases. In addition, the new cpds. (esp. those in which R3 is OH) are effective against trichomoniasis.
The invention relates to a microencapsulated amino acid composition and methods of manufacturing this composition. Amino acids, such as branched-chain amino acids, have low water solubility, poor hydrophilicity, and poor stability. Amino acids are thus difficult to be digested and absorbed. Consequently amino acids can hardly meet human needs of consuming. This microencapsulated amino acid composition that can quickly disperse and dissolve in cold water, resulting clear solution. The method includes (1) adding coating agents, wetting agents, or other excipients to the amino acid mixture, (2) modifying the surface of microencapsulated particles to considerably accelerate the wetting speed. In this composition, the weight ratio of amino acids and excipients is from 100/0.1 to 100/10.0. This invention delivers advantages over conventional products, such as instant dispersion and dissolution in water, transparent solution, no precipitation, no floating, no foam, increased shelf life, more convenient, and faster oral absorption. Therefore, the present invention is a good solution to the problems of amino acids, resolving the problems related to prior products. The present invention does not have unpleasant taste or odor that prior amino acids bring to consumers. The method of the present invention is simple and easy to be industrialized.
Provided are compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. Human Ii-RNAi constructs that effectively inhibit Ii expression in human cancer cells have been generated. The combination of different Ii-RNAi constructs that target different positions of Ii mRNA has a synergistic effect on Ii inhibition. Furthermore, specific promoters for driving Ii-RNAi expression are critical for the activity of Ii-RNAi in different types of cells. Active Ii-RNAi sequences were cloned into plasmids in which Ii-RNAi sequences are driven by either a CMV or an EF-1α; promoter. Compositions and methods are disclosed for inhibiting Ii and treating cancer. Provided are siRNAs and expression constructs comprising DNA sequences which encode siRNAs effective to inhibit Ii expression, cells containing such DNA constructs or siRNAs, and methods for use of the same.
PROBLEM TO BE SOLVED: To provide a make-up cosmetic which can change the texture of a make-up finish with one kind of the cosmetic, namely give a dual make-up finish. SOLUTION: This manicure cosmetic for a nail color cosmetic is characterized by containing one or more materials selected from silica, nylon powder and mica. The total content of one or more materials selected from silica, nylon powder and mica is preferably 1 to 5 wt.%, more preferably 1 to 3 wt.%, based on the manicure cosmetic. A pearl pigment or organic colorant is preferably contained except the powdery materials. The viscosity of the manicure cosmetic is preferably controlled to 50 to 200 mPa.sec. When left stand and then used, the manicure cosmetic exhibits a lustrous finish, and when impregnated and immediately used, the manicure cosmetic exhibits a mat finish.
Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
INTRODUCTION AND OBJECTIVES: Medical device companies have introduced new TFL machines, including Soltive (Olympus, Japan), Fiber Dust (Quanta System, Italy), and TFLDrive (Coloplast, France). The primary objective of this study is to compare our initial clinical experiences with TFL using those devices. Through this historical comparison of Thulium Fiber Laser systems for stone lithotripsy, we aim to advance our understanding and approach toward achieving safe and effective TFL parameters.
MATERIALS AND METHODS: The data for this comparative analysis were extracted from three distinct prospective series that were previously published, outlining our initial clinical experience with the Soltive (Olympus, Japan), FiberDust laser (Quanta System, Italy), and TFLDrive laser (Coloplast, France). Parameters such as stone size, stone density, laser-on time (LOT), and laser settings were meticulously recorded. Additionally, we assessed critical variables such as ablation speed (expressed in mm3/s) and Joules/mm3 for each lithotripsy procedure.
RESULTS: A total of 149 patients were enrolled in this study. Among them, 120 patients were subjected to analysis concerning renal stones. Statistically significant differences were observed in the median (IQR) stone volume: 650 (127-6027) mm3 for TFLDrive, 1800 (682.8-2760) mm3 for Soltive, and 1125 (294-4000) mm3 for FiberDust (p: 0.007); while there were no differences regarding stone density among the groups. Significant variations were identified in median (IQR) pulse energy, frequency, and total power. The Soltive group exhibited lower energy levels (0.3 J vs. 0.6 J, p: 0.002) but significantly higher pulse frequency (100 Hz vs. 17.5 Hz, p: 0.003) and total power (24 W vs. 11W, p: 0.001) compared to the other groups. Laser-on time showed no substantial differences across all three groups. Additionally, a statistically significant difference was observed in median J/mm3, with the TFLDrive group using higher values (24 J/mm3, p: 0.001), while the Soltive group demonstrated a higher median ablation speed of 1.16 mm3/s (p: 0.001). The overall complication rate remained low for all groups, with comparable stone-free rates.
CONCLUSION: By reducing pulsed frequency, we improved laser efficiency, but smaller volumes lead to decreased efficiency due to increased retropulsion and fragment movement. Further studies are needed to identify and establish the appropriate laser settings for this new technology.
One hundred postmenopausal women living in the urban area of Valencia were invited to participate in a cross-sectional study in which a list of clinical and analytical risk factors for cardiovascular disease were assessed. Clinical factors included weight, waist circumference, body mass index and blood pressure. Analytical parameters included lipidogram, serum glucose and insulin, thyroid hormones (TSH and total T4), vitamin D, ultra-sensitive C-reactive protein, estradiol, and osteoprotegerin. Imaging studies were performed to identify the atherosclerotic burden at the carotid artery (intima-media thickness, measured by a high frequency ultrasound probe), and the coronaries (both coronary artery calcium(CAC) score and the degree of lumen stenosis). Genetic susceptibility was measured by studying single nucleotide polymorphisms of the estrogen receptor. The independent effect of each variable was analyzed with multivariate analysis.
Genistein is a natural product found in soy beans; its consumption has been associated with a low incidence of metastatic prostate cancer. Genistein is a known protein-tyrosine kinase inhibitor, and in preclinical studies it has been shown to increase cell adhesion. Increases in cell adhesion in vivo would phenotypically reverse the first step in the metastatic cascade, potentially preventing metastasis formation, and is consistent with epidemiologic findings. This study seeks to determine the pharmacokinetics of genistein in humans by administering a single dose of genistein and performing a pharmacokinetic analysis. Patients will be treated with two formulations of genistein (a 43% genistein preparation or a 90% preparation). This is a phase I study, and patients will be treated on one of three dosing levels. Patients will be randomly assigned to receive one formulation first, followed by a washout period, and will then receive the second preparation (i.e., a randomized cross over design). Information from this study will be used to optimally design a multiple dose study wherein patients will be treated for longer periods of time. The duration of this study is estimated to be about 4 weeks long for each patient.
Obesity and its complications constitute a main threat to global human health. The purpose of this investigation was to explore the influences of Clostridium tyrobutyricum (Ct) on lipid metabolism, intestinal barrier function, and intestinal microbiome in obese mice induced by a high-fat diet (HFD). After establishing the obesity model, 107 CFU/mL and 108 CFU/mL C. tyrobutyricum were used to intervene in HFD-fed mice by gavage for six weeks, and indexes related to obesity were measured. In the liver of HFD-fed mice, the results revealed that C. tyrobutyricum reduced liver weight and the levels of triglyceride (TG), total cholesterol (TC), and nonesterified fatty acid (NEFA), along with decreasing red lipid droplets and fat vacuoles. After C. tyrobutyricum intervention, the mRNA expression of peroxisome proliferator-activated receptor-γ (PPARγ) was downregulated, and AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor-α (PPARα), adipose triglyceride lipase (ATGL), and hormone-sensitive lipase (HSL) were upregulated in the liver. Additionally, C. tyrobutyricum alleviated intestinal morphology injury caused by HFD, decreased the expression of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and IL-1β in the colon, and upregulated tight junction protein expression. In addition, 16S rRNA sequencing revealed that C. tyrobutyricum increases the diversity of intestinal microbiota. Overall, C. tyrobutyricum improved HFD-induced lipid metabolism disorders, preserved the intestinal barrier's integrity, and modulated the structure of the intestinal microbiome. These findings provide a novel insight into the role of C. tyrobutyricum as a probiotic in regulating lipid metabolism.
The investigators will conduct a prospective, single-arm, non-interventional study using the Emerald device to monitor the behavior of individuals enrolled in the parent study (ClinicalTrials.gov identifier NCT04430517). Investigators aim to enroll approximately 40 individuals aged 18 -89 (inclusive) with either MCI or mild AD who will have Emerald deployed in their home for up to 12 weeks, spanning the time of approval of parent study screening and formal study enrollment. The Emerald device is a radio-wave sensor that uses signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of subjects without physical contact or effort by the user, i.e. it neither requires the subject to wear a sensor nor record any data. Emerald works by transmitting low-powered radio signals, 1000x less than Wi-Fi, that reflect off of the subject and return back to the device. If the user moves their arm or leg, or their chest expands and contracts from breathing, that movement changes how the signal reflects off of their body. Emerald records these reflections and processes them using algorithms that convert the radio signals into movement data, breathing rate, sleep stages (Awake, Light, Deep and REM), and key sleep parameters. The device will be deployed in the bedroom of each subject to capture behavior continuously.
A PET/CT tracer having selectivity for different lung cancer cells, a preparation method therefor and use thereof. The PET/CT tracer is a compound represented by formula I, or a salt or stereoisomer thereof, wherein R1 and R2 are each independently selected from H or C1-C5 alkyl, and X is independently selected from 11C, 18F, 19F, 15O, or 13N. The prepared 18F-PET/CT tracer can be selectively taken in by different carcinogenic driver gene mutant lung cancer cells. Test results show that the 18F-PET/CT tracer is expected to achieve high quality imaging in an NRas Q61K tumor model, and has certain selectivity for different carcinogenic driver gene mutant lung cancers. The tracer is different from 18F-FDG that may lead to high-concentration imaging in any lesion due to increased glucose metabolism, and is expected to make up for the deficiency of imaging by using 18F-FDG alone. Therefore, the 18F-PET/CT tracer is expected to be applied to PET/CT iconography and change the situation of lack of tracers on lung cancers.
PROBLEM TO BE SOLVED: To provide the subject agent containing onion or its processed product, capable of increasing the steroid hormone, especially testosterone in blood plasma and effective for the promotion of gonad function of male and the prevention and treatment of mammary cancer, etc. SOLUTION: This agent contains onion or its processed product, preferably onion juice or onion vinegar. The onion juice can be produced e.g. by squeezing raw onion with a juicer, etc., boiling the juice for a short time and filtering the product having decreased viscosity. The onion vinegar can be produced e.g. by subjecting the onion juice to alcoholic fermentation and then to acetic acid fermentation.
BACKGROUND: Postoperative complications are an integral part of valve surgery. Common complications include hematomas, bleeding, valve dehiscence, paravalvular leak, and acute PV thrombosis. With the available data from published articles, the rate of all valve-related complications is 0.7 to 3.5% per patient annually. [1] The pathology involved is multifactorial, often blood vessel injury leading to bleeding and hematoma. Although postoperative complications are evident, incidental diagnosis of a cardiac mass in an asymptomatic and hemodynamically stable patient postoperatively is crucial, requiring non-invasive imaging for immediate surgical action.
CASE PRESENTATION: A woman in her 50s presented with chief complaints of worsening dyspnoea with suddenonset and chest pain. Clinical findings showed apex shifted downward and outward, wide split S2, and a mid systolic murmur radiating to the mid axillary line. Twelve-lead ECG showed LA enlargement, that aligned with X-ray findings. 2D Echocardiography revealed MVP with severe MR and a dilated LV. The patient underwent successful mitral valve replacement as per ACC/AHA class I recommendation. However, postoperative TTE showed a remarkably large mass measuring 5.6 cm*4.6 cm in the RA. Reexploration was performed, followed by mass excision. Plenty of organized clots were seen compressing the RA. TEE showed no evidence of mass. Following stabilization,the patient was discharged considering optimal INR values and prosthetic valve function assessed by echocardiography. The patient's symptoms improved during the first follow-up.
CONCLUSION: Although postoperative cardiac complications are common, appropriate diagnosis with TTE and TEE has benefited surgeons. TEE-guided reexploration aids surgeons in decision-making and strategic approaches. Failure to diagnose such complications in asymptomatic patients can ultimately complicate the procedure. Henceforth, sonographers must be skilled in the detection and identification of unusual complications to guide redo interventions. Such an approach minimizes mortality, redo procedures, and avoids CPB hence reducing long-term prognosis and outcomes with valve replacement.
Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.
PURPOSE:To provide the subject composition for oral cavity application, containing a beta-D-glycopyranoside derivative and an alcohol, having improved stimulation of alcohol and giving excellent feeling during and after use. CONSTITUTION:The objective composition contains a compound of formula (R is 2-7C alkyl) and an alcohol. The compound of formula is e.g. ethyl-beta-D- glycoside or propyl-beta-D-glycoside. The alcohol is used for the cleaning of oral cavity and is e.g. geraniol-modified alcohol or haloacetylated sucrose-modified alcohol. Generally, the amounts of the compound of formula and the alcohol are about 0.1-10wt.% and about 5-70wt.% based on the total amount of the composition, respectively.
Provided is a PD-L1 knockout CAR-T transgenic vector for suppressing immune escape, comprising: an ampicillin resistant (AmpR) sequence as indicated by SEQ ID NO. 1; a prokaryotic replicon pUC Ori sequence as indicated by SEQ ID NO. 2; a viral replicon SV40 Ori sequence as indicated by SEQ ID NO. 3; an enhanced woodchuck hepatitis virus posttranscriptional regulatory element (eWPRE) as indicated by SEQ ID NO. 11; a human EF1α promoter as indicated by SEQ ID NO. 12; a lentivirus packaging  cis -element for lentivirus packaging; human PD-L1 humanized single-chain antibodies PDL1scFv1 as indicated by SEQ ID NO. 21, PDL1scFv2 as indicated by SEQ ID NO. 22, or PDL1scFv3 as indicated by SEQ ID NO. 23; an IRES ribosome binding sequence as indicated by SEQ ID NO. 25; an IL-6 signal peptide as indicated by SEQ ID NO. 26; a humanized antibody Fc fragment as indicated by SEQ ID NO. 27; and a second generation or third generation chimeric antigen receptor (CAR) combining the functions of identification, transfer, and activation. Further provided is a method for preparing the vector and an application of the vector in preparing a pharmaceutical drug for suppressing immune escape.